Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically its proprietary BeadArray technology. The company targets life sciences, pharmaceutical, agriculture, and food industries. As of the reporting date, the company had no commercially available microarray products, with revenues primarily derived from government grants and initial sales of custom oligonucleotides and SNP genotyping services.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 |
Six Months Ended June 30, 2001 |
Six Months Ended June 30, 2000 |
|---|---|---|---|
| Revenue | $469,840 | $1,033,532 | $161,857 |
| Net Loss | $(5,892,927) | $(10,811,004) | $(10,115,396) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.37) | $(4.27) |
| Operating Cash Flow | N/A | $(5,380,244) | $(2,803,978) |
| Investing Cash Flow | N/A | $(99,676,358) | $(881,191) |
| Cash & Equivalents (End of Period) | $11,423,458 (June 30, 2001) | ||
| Total Investments | $98,540,477 (June 30, 2001) | ||
| Total Assets | $130,152,392 (June 30, 2001) | ||
| Accumulated Deficit | ~$36.1 million (June 30, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly to $1.03 million for the six months ended June 30, 2001, compared to $0.16 million in the prior year period. This growth was driven by the initiation of commercial sales of custom oligonucleotides and SNP genotyping services, though government grants still accounted for 86% of total revenue.
- Expense Increases: Research and Development (R&D) expenses rose to $9.54 million (six months 2001) from $6.67 million (six months 2000), primarily due to increased staffing to support commercialization. General and Administrative expenses increased to $2.49 million from $1.56 million due to public company compliance costs and staffing.
- Cash Position: While total liquid assets (cash, equivalents, and investments) remained robust at approximately $110 million, cash and cash equivalents specifically dropped from $116.1 million at year-end 2000 to $11.4 million at June 30, 2001. This decrease was due to a strategic reinvestment of $99.7 million into longer-term investment securities.
- Deferred Revenue: Deferred revenue increased to $8.9 million from $5.0 million at the end of 2000, reflecting payments received from strategic partners prior to revenue recognition.
Outlook, Risks, and Management Commentary
- Commercialization Timeline: The company expects to commercialize its first products under its strategic partnership with Applied Biosystems in mid-2002. A delay was announced earlier in 2001 regarding this product introduction.
- Liquidity: Management expects current cash, investments, and funding from alliances to be sufficient to fund operations for at least the next 24 months. However, the company anticipates incurring additional operating losses as it scales R&D and commercialization efforts.
- Capital Expenditures: The company is constructing new facilities and expects to assume a $24 million mortgage at an 8.41% fixed rate upon closing in September 2001. Progress payments of $5 to $6 million are expected in the third quarter of 2001.
- Key Risks:
- Profitability: The company has an accumulated deficit of $36.1 million and expects to continue incurring net losses. There is no guarantee of achieving profitability.
- Partnership Dependence: Success is heavily reliant on the partnership with Applied Biosystems for instrument development and marketing. Failure of this partner to deliver could halt commercialization.
- Manufacturing: The company has limited manufacturing experience and relies on single sources for certain components (e.g., fiber optic bundles).
- Market Acceptance: The target markets for genetic analysis are emerging, and the company's technology is unproven compared to existing methods.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of government grant revenue versus the growth trajectory of commercial product sales (oligonucleotides and SNP services).
- Applied Biosystems Partnership: Monitor the status of the mid-2002 product launch and the partner's progress on instrument development.
- Cash Burn Rate: Assess the adequacy of the $110 million liquid asset base against the projected $5–$6 million facility payments and ongoing operating losses.
- Debt Obligations: Confirm the terms and closing of the $24 million mortgage expected in September 2001.
- Stock-Based Compensation: Review the impact of the $17.9 million deferred compensation pool and its amortization on future earnings.